Chloë Prince’s Post

A quarter of the 21st century has passed, yet the promise of affordable personalised precision medicine remains unfulfilled. Despite innovations, the life sciences industry is disconnected from real patient care. Our article explores how current R&D practices and entrenched biases hinder progress and highlights the urgent need for innovative solutions that align with the broader healthcare landscape. Discover why the future of medicine depends on reimagining our approach to therapeutic development in our latest article by our Chief Medical Officer Atanas Todorov, MD-PhD: “The life sciences industry urgently needs medical attention!” Dive deeper into these insights and more by downloading the full article: https://lnkd.in/eGBgNx-E #Healthcare #Innovation #Patientcare #Arcondis #WeMakeHealthcareBetter

Boosting trust in clinical trials will increase accessibility and accelerate clinical research and drive better, more holistic clinical outcomes. Uncover the insights driving advancements in medical research and how these can be applied to your organisation ➡️ https://ow.ly/snlt50SC56c #ClinicalResearch #Healthcare

FOMAT's Bold Move Ignites: 4 Physician Groups Unite to Transform Santa Maria's Healthcare & Clinical Research. Discover the synergy between FOMAT Medical Research and top medical specialists, setting new standards for patient care and innovation. Ready to see healthcare transformation in action? Click to read the full press release. https://lnkd.in/eDVFM_x9 #FOMATInnovation #BetterCare #ClinicalTrialsRevolution

How valid and relevant is the sentiment on the "power of partnerships and collaborations" five years after publication? Thoughts? Medical affairs' partnerships with governments, academia, research organisations and new entrants to the field are pivotal for healthcare delivery transformation. In addition, medical affairs professionals are uniquely qualified to contribute to the ongoing (r)evolution in healthcare to improve patient outcomes. https://lnkd.in/ek3hbzg8 Andrey Ipatov Filip Surmont Carmen Moreno Redondo Maarten Beekman Ryan James Bate #medicalaffairs #realworldevidence #realworlddata

MTRC shares the most relevant and impactful publications in the field of market access and HEOR for medical technologies in Europe through its Publications Digest. In a recent publication, Milstein et al. conducted a comprehensive review of reforms to Diagnosis-Related Group (DRG) payment systems across ten high-income countries. The authors aimed to provide an overview of the latest reforms and their evidence to date, highlighting a shift from volume-based to value-based payment mechanisms in hospital care. The findings revealed diverse reform trends, including reductions in DRG-based payments, episode-based payments, and incentives to promote care delivery in less costly settings, reflecting efforts to improve the quality of care while controlling healthcare expenditures: https://lnkd.in/dMaWCtwz

MTRC shares the most relevant and impactful publications in the field of market access and HEOR for medical technologies in Europe through its Publications Digest. In a recent publication, Milstein et al. conducted a comprehensive review of reforms to Diagnosis-Related Group (DRG) payment systems across ten high-income countries. The authors aimed to provide an overview of the latest reforms and their evidence to date, highlighting a shift from volume-based to value-based payment mechanisms in hospital care. The findings revealed diverse reform trends, including reductions in DRG-based payments, episode-based payments, and incentives to promote care delivery in less costly settings, reflecting efforts to improve the quality of care while controlling healthcare expenditures: https://lnkd.in/eThnSjaj

How do you transform the UK Clinical Trials Gateway? My colleagues at PA reimagined the service, turning it from a 'shop window' website where people could find out about clinical trials into a sophisticated online service for registering as a potential research participant. #clinicaltrials #pharmainnovation

How to avoid the dangers of duplicate subjects in clinical trials? Verified Clinical Trials' Kerri Weingard discusses this topic with Moe Alsumidaie of clinicaltrialvanguard.com. The issue of duplicate and professional research subjects is prevalent, making it a "must have" for all clinical trials. Check out the interview here: https://lnkd.in/dV--z-KQ Learn more at: https://lnkd.in/etwhixy #clinicaltrials #research #healthcare #professionalresearchsubjects

How to avoid the dangers of duplicate subjects in clinical trials? Verified Clinical Trials' Kerri Weingard discusses this topic with Moe Alsumidaie of clinicaltrialvanguard.com. The issue of duplicate and professional research subjects is prevalent, making it a "must have" for all clinical trials. Check out the interview here: https://lnkd.in/dhTqtatD Learn more at: https://lnkd.in/eRK5k36 #clinicaltrials #research #healthcare #professionalresearchsubjects

How to avoid the dangers of duplicate subjects in clinical trials? Verified Clinical Trials' Kerri Weingard discusses this topic with Moe Alsumidaie of clinicaltrialvanguard.com. The issue of duplicate and professional research subjects is prevalent, making it a "must have" for all clinical trials. Check out the interview here: https://lnkd.in/dhTqtatD Learn more at: https://lnkd.in/eRK5k36 #clinicaltrials #research #healthcare #professionalresearchsubjects